Compositions for the treatment of sarcopenia or disuse atrophy
AssigneesAssociation Institut De Myologie, Inserm (Institut National De La Sante Et De La Recherche Medicale), Sorbonne Universite
InventorsFrance PIETRI-ROUXEL, Sestina FALCONE
Life of this patent
Estimating the term…
Abstract
The present invention relates to a substance that activates the GDF5 pathway, for use in a method for the treatment of age-related sarcopenia or disuse atrophy.
Claims14
A GDF5 pathway-activating substance for use in a method for the treatment or prevention of sarcopenia or disuse atrophy.
A GDF5 pathway-activating substance for use in treating or preventing muscle weakness in a myopathy or neuromuscular disease, alone or in combination with a treatment of said myopathy or neuromuscular disease.
A pharmaceutical composition comprising a GDF5 pathway-activating substance and a pharmaceutically acceptable carrier.
A GDF5 pathway-activating substance, for use as a medicament.
A method for the diagnosis of sarcopenia in a subject, comprising determining the level of GDF5 in a biological sample of said subject.
Dependencies are inferred from the claim text.